MA37946A1 - Traitement de la polyarthrite rhumatoïde - Google Patents

Traitement de la polyarthrite rhumatoïde

Info

Publication number
MA37946A1
MA37946A1 MA37946A MA37946A MA37946A1 MA 37946 A1 MA37946 A1 MA 37946A1 MA 37946 A MA37946 A MA 37946A MA 37946 A MA37946 A MA 37946A MA 37946 A1 MA37946 A1 MA 37946A1
Authority
MA
Morocco
Prior art keywords
rheumatoid arthritis
treatment
relates
csf antibodies
mor103
Prior art date
Application number
MA37946A
Other languages
English (en)
Other versions
MA37946B1 (fr
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA37946A1 publication Critical patent/MA37946A1/fr
Publication of MA37946B1 publication Critical patent/MA37946B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps anti-gm-csf destinés à être utilisés dans le traitement de la polyarthrite rhumatoïde. L'invention concerne des anticorps anti-gm-csf, en particulier mor103, qui sont administrés à des patients souffrant de la polyarthrite rhumatoïde à des dosages qui sont avantageux dans des conditions cliniques.
MA37946A 2012-09-20 2013-09-19 Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde MA37946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
PCT/EP2013/069501 WO2014044768A1 (fr) 2012-09-20 2013-09-19 Traitement de la polyarthrite rhumatoïde

Publications (2)

Publication Number Publication Date
MA37946A1 true MA37946A1 (fr) 2018-01-31
MA37946B1 MA37946B1 (fr) 2018-09-28

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37946A MA37946B1 (fr) 2012-09-20 2013-09-19 Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde

Country Status (22)

Country Link
US (4) US20150246969A1 (fr)
EP (3) EP3916013A1 (fr)
JP (4) JP2015533806A (fr)
KR (4) KR20230041086A (fr)
CN (2) CN104995210A (fr)
AU (2) AU2013320261A1 (fr)
BR (1) BR112015006189B1 (fr)
CL (2) CL2015000696A1 (fr)
CR (1) CR20150153A (fr)
DO (1) DOP2015000070A (fr)
EA (1) EA031489B1 (fr)
HK (1) HK1208231A1 (fr)
IL (1) IL237554B (fr)
IN (1) IN2015KN00657A (fr)
MA (1) MA37946B1 (fr)
MX (2) MX382937B (fr)
MY (1) MY175388A (fr)
PE (1) PE20151079A1 (fr)
PH (1) PH12015500591A1 (fr)
SG (2) SG10201803778PA (fr)
UA (1) UA117228C2 (fr)
WO (1) WO2014044768A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3916013A1 (fr) * 2012-09-20 2021-12-01 MorphoSys AG Traitement de la polyarthrite rhumatoïde avec anticorps dirigé contre gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
AR100268A1 (es) * 2014-05-07 2016-09-21 Takeda Gmbh Formulación líquida que comprende compuesto neutralizante de gm-csf
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
PL3328887T3 (pl) 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
EP3623382A1 (fr) 2018-09-14 2020-03-18 Universität Zürich Ligands vers gm-csf ou un récepteur gm-csf destinés à être utilisés dans une leucémie chez un patient ayant subi une allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (fr) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Antagonistes du gm-csf destinés à être utilisés dans le traitement de la covid-19 pulmonaire sévère, du syndrome de libération de cytokine et/ou du syndrome de détresse respiratoire aiguë
WO2025218746A1 (fr) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Méthodes de traitement de la polyarthrite rhumatoïde

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP2001501619A (ja) 1996-10-04 2001-02-06 アムジェン インコーポレーテッド ｍｐｌリガンドを含有する医薬組成物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007120656A2 (fr) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
WO2008042261A2 (fr) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anticorps anti-charbon, ses formulations, et procédés d'utilisation
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US20100209434A1 (en) * 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
AR065910A1 (es) * 2007-04-02 2009-07-08 Genentech Inc Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
WO2008122415A1 (fr) 2007-04-05 2008-10-16 Sandoz Ag Formulations aqueuses stables de g-csf
WO2008157282A1 (fr) * 2007-06-18 2008-12-24 Genentech, Inc. Marqueurs biologiques prédictifs d'une réponse d'arthrite rhumatoïde à des antagonistes de cellule b
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
MX2010005291A (es) 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
ES2978209T3 (es) * 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
EP2427495A1 (fr) * 2009-05-05 2012-03-14 MorphoSys AG Traitement pour la sclérose en plaques
RS53010B (sr) 2009-12-31 2014-04-30 Arven Ilac Sanayi Ve Ticaret A.S. Novi postupak za pripremu g-csf (faktora stimulacije kolonije granulocita)
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
EP3916013A1 (fr) * 2012-09-20 2021-12-01 MorphoSys AG Traitement de la polyarthrite rhumatoïde avec anticorps dirigé contre gm-csf

Also Published As

Publication number Publication date
PH12015500591B1 (en) 2015-05-11
MX2015003644A (es) 2015-09-25
UA117228C2 (uk) 2018-07-10
MX382937B (es) 2025-03-13
KR20220028177A (ko) 2022-03-08
AU2016250388B2 (en) 2018-07-19
CL2015000696A1 (es) 2015-10-23
US20210130451A1 (en) 2021-05-06
CL2018000933A1 (es) 2018-07-20
US20150246969A1 (en) 2015-09-03
MA37946B1 (fr) 2018-09-28
JP2018138551A (ja) 2018-09-06
EP2897977A1 (fr) 2015-07-29
IL237554A0 (en) 2015-04-30
AU2016250388A1 (en) 2016-11-17
US20180230208A1 (en) 2018-08-16
HK1208231A1 (en) 2016-02-26
US10913792B2 (en) 2021-02-09
IN2015KN00657A (fr) 2015-07-17
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (fr) 2014-03-27
CA2884124A1 (fr) 2014-03-27
SG10201803778PA (en) 2018-06-28
CN109999195A (zh) 2019-07-12
KR20240091288A (ko) 2024-06-21
JP2022169709A (ja) 2022-11-09
BR112015006189A2 (pt) 2019-11-26
IL237554B (en) 2019-12-31
KR20150056846A (ko) 2015-05-27
BR112015006189B1 (pt) 2022-04-05
EP3345923A1 (fr) 2018-07-11
CN104995210A (zh) 2015-10-21
EA201590359A1 (ru) 2015-08-31
DOP2015000070A (es) 2015-08-16
PH12015500591A1 (en) 2015-05-11
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
JP2024156992A (ja) 2024-11-06
MX2021006111A (es) 2021-07-07
EA031489B1 (ru) 2019-01-31
US20240417455A1 (en) 2024-12-19
EP3916013A1 (fr) 2021-12-01
CR20150153A (es) 2015-09-14
JP2015533806A (ja) 2015-11-26
PE20151079A1 (es) 2015-08-07
AU2013320261A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA40770B1 (fr) Dérivés d'imidazoles pentacyclic fusionnés
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EP2683382A4 (fr) Régimes posologiques pour le traitement de la maladie de fabry
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MA38478A1 (fr) Anticorps anti-pac1 humains
MA38161A1 (fr) Anticorps anti-bmp-6
MA37777B1 (fr) Préparation pharmaceutique
MA37317B1 (fr) Formulation d'anticorps il-17
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3
ATE522537T1 (de) (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis